array:23 [ "pii" => "S0025775315300075" "issn" => "00257753" "doi" => "10.1016/S0025-7753(15)30007-5" "estado" => "S300" "fechaPublicacion" => "2014-12-01" "aid" => "70115" "copyright" => "Elsevier España, S.L.U.. Todos los derechos reservados" "copyrightAnyo" => "2014" "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2014;143 Supl 3:30-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 355 "formatos" => array:2 [ "HTML" => 241 "PDF" => 114 ] ] "itemSiguiente" => array:18 [ "pii" => "S0025775315300087" "issn" => "00257753" "doi" => "10.1016/S0025-7753(15)30008-7" "estado" => "S300" "fechaPublicacion" => "2014-12-01" "aid" => "70116" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2014;143 Supl 3:35-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 450 "formatos" => array:2 [ "HTML" => 240 "PDF" => 210 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Situaciones especiales en la esclerosis múltiple" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "35" "paginaFinal" => "38" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Special cases of multiple sclerosis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Mar Mendibe Bilbao" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Mar" "apellidos" => "Mendibe Bilbao" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315300087?idApp=UINPBA00004N" "url" => "/00257753/00000143000000S3/v2_201502280340/S0025775315300087/v2_201502280340/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0025775315300063" "issn" => "00257753" "doi" => "10.1016/S0025-7753(15)30006-3" "estado" => "S300" "fechaPublicacion" => "2014-12-01" "aid" => "70114" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 0 "subdocumento" => "fla" "cita" => "Med Clin. 2014;143 Supl 3:23-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 386 "formatos" => array:2 [ "HTML" => 264 "PDF" => 122 ] ] "es" => array:10 [ "idiomaDefecto" => true "titulo" => "Tratamientos orales en esclerosis múltiple" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "23" "paginaFinal" => "29" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Oral treatments in multiple sclerosis" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José Eustasio Meca-Lallana, Rocío Hernández-Clares, Ester Carreón-Guarnizo" "autores" => array:3 [ 0 => array:2 [ "nombre" => "José Eustasio" "apellidos" => "Meca-Lallana" ] 1 => array:2 [ "nombre" => "Rocío" "apellidos" => "Hernández-Clares" ] 2 => array:2 [ "nombre" => "Ester" "apellidos" => "Carreón-Guarnizo" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315300063?idApp=UINPBA00004N" "url" => "/00257753/00000143000000S3/v2_201502280340/S0025775315300063/v2_201502280340/es/main.assets" ] "es" => array:11 [ "idiomaDefecto" => true "titulo" => "Anticuerpos monoclonales para el tratamiento de la esclerosis múltiple" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "30" "paginaFinal" => "34" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Victoria Galán Sánchez-Seco, Ignacio Casanova Peño, Rafael Arroyo González" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Victoria Galán" "apellidos" => "Sánchez-Seco" ] 1 => array:2 [ "nombre" => "Ignacio" "apellidos" => "Casanova Peño" ] 2 => array:4 [ "nombre" => "Rafael" "apellidos" => "Arroyo González" "email" => array:1 [ 0 => "rafaelarroyo09@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unidad de Enfermedades Desmielinizantes, Hospital Clínico San Carlos, Madrid, España" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "*" "correspondencia" => "Autor para correspondencia." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Monoclonal antibodies for the treatment of multiple sclerosis" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec464975" "palabras" => array:8 [ 0 => "Esclerosis múltiple" 1 => "Natalizumab" 2 => "Alemtuzumab" 3 => "Daclizumab" 4 => "Rituximab" 5 => "Ocrelizumab" 6 => "Ofatumumab" 7 => "BIIB033" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec464974" "palabras" => array:8 [ 0 => "Multiple sclerosis" 1 => "Natalizumab" 2 => "Alemtuzumab" 3 => "Daclizumab" 4 => "Rituximab" 5 => "Ocrelizumab" 6 => "Ofatumumab" 7 => "BIIB033" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Hasta mediados de los años noventa, con la aparición del interferón beta y el acetato de glatirámero, no existía tratamiento para la esclerosis múltiple (EM). Sin embargo, debido a su moderado potencial terapéutico en algunos pacientes, se continuó con una amplia búsqueda encaminada a encontrar nuevas y más efectivas estrategias de tratamiento, centrando buena parte de los esfuerzos en los anticuerpos monoclonales (AcMo). A finales de 2004 fue aprobado natalizumab, el primer AcMo para el tratamiento de la EM, que representó un importantísimo avance en el campo de la neuroinmunología. Hoy en día, la experiencia con natalizumab es amplia y existen otros AcMo (alemtuzumab, daclizumab, rituximab, ocrelizumab, ofatumumab y anti-lingo-1) pendientes de comercializar, o en fases II y II de estudio con resultados prometedores. En esta revisión se analizan los resultados de eficacia y seguridad de todos ellos.</p></span>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Until the mid 1990s, with the appearance of interferon beta and glatiramer acetate, there was no treatment for multiple sclerosis (MS). However, due to their moderate therapeutic potential in some patients, a broad search was continued to find new and more effective treatment strategies, largely concentrated on monoclonal antibodies (MOAB). Natalizumab, the first MOAB for the treatment of MS, was approved at the end of 2004, representing a major advance in the field of neuroimmunology. Today, there is broad experience with natalizumab and other MOAB (alemtuzumab, daclizumab, rituximab, ocrelizumab, ofatumumab and anti-lingo-1) that are pending commercialization or are under phase II or III of development with promising results. The present review analyzes the efficacy and safety results of all these drugs.</p></span>" ] ] ] "idiomaDefecto" => "es" "url" => "/00257753/00000143000000S3/v2_201502280340/S0025775315300075/v2_201502280340/es/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/00257753/00000143000000S3/v2_201502280340/S0025775315300075/v2_201502280340/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315300075?idApp=UINPBA00004N" ]
Información de la revista
Compartir
Descargar PDF
Más opciones de artículo
Anticuerpos monoclonales para el tratamiento de la esclerosis múltiple
Monoclonal antibodies for the treatment of multiple sclerosis
Victoria Galán Sánchez-Seco, Ignacio Casanova Peño, Rafael Arroyo González
Autor para correspondencia
Unidad de Enfermedades Desmielinizantes, Hospital Clínico San Carlos, Madrid, España